Immunization, Vaccines and Biologicals
The Immunization, Vaccines and Biologicals department is responsible for targeting vaccine-preventable diseases, guiding immunization research and establishing immunization policy.

Ebola disease

WHO / Jimmy Adriko
A Hygienist prepares a nurse before entering the Ebola treatment center at Mubende Hospital, Uganda (29 Sept 2020). Uganda confirmed an Ebola outbreak on 20 Sept 2022. WHO supported unit setup, deployment, and training.
© Credits

Ebola disease is a rare but severe illness that affects humans and other primates and is often fatal. It is caused by a group of viruses known as orthoebolaviruses.  

There are four species of orthoebolaviruses known to cause disease in humans:   

  • Ebola virus (EBOV), which causes Ebola virus disease (EVD) 
  • Sudan virus (SUDV), which causes Sudan virus disease (SVD) 
  • Taï Forest virus, which causes Taï Forest virus disease 
  • Bundibugyo virus (BDBV), which causes Bundibugyo virus disease (BVD).  




Currently, there is one licensed and WHO-prequalified vaccine, Ervebo®, available for the prevention of EVD, caused by EBOV. Administered as a single dose, Ervebo® is recommended for use during EVD outbreaks. 

The Ervebo® vaccine can be accessed through the International Coordinating Group (ICG) on Vaccine Provision global stockpile. For preventive vaccination of health-care and frontline workers, requests for Ervebo® vaccines can be made through Gavi Preventive Ebola vaccination

At present, there are no licensed vaccines for SVD, Taï Forest virus disease, or BVD. However, several candidate vaccines are under development.  

An outbreak of Ebola disease caused by the Bundibugyo virus was declared in the Democratic Republic of Congo and Uganda in 2026. The WHO has classified the event as a Public Health Emergency of International Concern (PHEIC) on 15 May 2026 due to Bundibugyo virus disease severity and potential for international spread.  

WHO does not currently recommend the use of Ervebo® vaccine for outbreaks caused by Bundibugyo virus because there is insufficient evidence that it provides protection against this virus. Vaccination is only one component of a comprehensive Ebola outbreak response, which also includes surveillance, laboratory testing, case management, infection prevention and control measures, safe and dignified burials, and community engagement.  

Previously, WHO declared a PHEIC on 8 August 2014 in response to the West African Ebola outbreak (2014–2016), and again on 17 July 2019 during the Ebola outbreak in the eastern Democratic Republic of the Congo (2018–2020). 



WHO publications

WHO target product profile for Bundibugyo virus disease vaccines, 14 July 2026

Bundibugyo virus disease, which is caused by Bundibugyo virus, is a severe filovirus infection with epidemic potential that requires the development of...

WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks, 28 May 2026

This emergency guidance document outlines the World Health Organization (WHO) position on the use of the licensed Ebola virus vaccine Ervebo® during...

Extraordinary meeting of the 
Strategic Advisory Group of 
Experts on Immunization on Ebola 
vaccination, May 2024: conclusions 
and recommendations

The Strategic Advisory Group of Experts (SAGE) on Immunization held an extraordinary meeting on 7 May 2024 on ebola vaccines. This report summarizes the...



News